Literature DB >> 29185062

Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Teo Soleymani1, Soumya M Reddy2, Jeffrey M Cohen3, Andrea L Neimann4.   

Abstract

PURPOSE OF REVIEW: Diagnosis and treatment of psoriatic arthritis (PsA) can be challenging and require a multidisciplinary approach. This review provides an overview of combined dermatology-rheumatology clinics. RECENT
FINDINGS: Combined dermatology-rheumatology clinics have emerged to optimize integrated care for patients with psoriasis and PsA. There are over 20 such clinics across the USA. These clinics facilitate multidisciplinary care for patients with psoriasis and PsA and have been found to improve outcomes and enhance both patient and physician satisfaction and knowledge. Challenges presented by these clinics include appropriate scheduling for both dermatologists and rheumatologists and proving the benefits of the clinics to obtain institutional support. Combined dermatology-rheumatology clinics are a novel model of care for patients with psoriasis and PsA. They improve outcomes, patient and physician satisfaction, and efficiency. As more of these clinics are established, we must further understand their impact on outcomes and care processes.

Entities:  

Keywords:  Biologics; Dermatology; Methotrexate; PsA; Psoriasis; Psoriatic arthritis; Rheumatology

Mesh:

Year:  2017        PMID: 29185062     DOI: 10.1007/s11926-017-0706-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  87 in total

1.  Poor adherence to treatments: a fundamental principle of dermatology.

Authors:  Saba M Ali; Robert T Brodell; Rajesh Balkrishnan; Steven R Feldman
Journal:  Arch Dermatol       Date:  2007-07

Review 2.  How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases.

Authors:  Dominique L P Baeten; Vijay K Kuchroo
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 3.  Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.

Authors:  Axel Patrice Villani; Marie Rouzaud; Morgane Sevrain; Thomas Barnetche; Carle Paul; Marie-Aleth Richard; Marie Beylot-Barry; Laurent Misery; Pascal Joly; Michel Le Maitre; Selim Aractingi; François Aubin; Alain Cantagrel; Jean-Paul Ortonne; Denis Jullien
Journal:  J Am Acad Dermatol       Date:  2015-06-06       Impact factor: 11.527

4.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

5.  IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

Authors:  James G Krueger; Scott Fretzin; Mayte Suárez-Fariñas; Patrick A Haslett; Krista M Phipps; Gregory S Cameron; Juliet McColm; Artemis Katcherian; Inna Cueto; Traci White; Subhashis Banerjee; Robert W Hoffman
Journal:  J Allergy Clin Immunol       Date:  2012-06-05       Impact factor: 10.793

6.  A prospective study of patient adherence to topical treatments: 95% of patients underdose.

Authors:  Andreas Storm; Eva Benfeldt; Stig Ejdrup Andersen; Jørgen Serup
Journal:  J Am Acad Dermatol       Date:  2008-09-24       Impact factor: 11.527

7.  Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study).

Authors:  L C Coates; T Aslam; F Al Balushi; A D Burden; Esther Burden-Teh; E Burden-The; A R Caperon; R Cerio; C Chattopadhyay; H Chinoy; M J D Goodfield; L Kay; S Kelly; B W Kirkham; C R Lovell; H Marzo-Ortega; N McHugh; R Murphy; N J Reynolds; C H Smith; E J C Stewart; R B Warren; R Waxman; H E Wilson; P S Helliwell
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

8.  Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.

Authors:  Jashin J Wu; Kwun-Yee T Poon; Jennifer C Channual; Albert Yuh-Jer Shen
Journal:  Arch Dermatol       Date:  2012-11

9.  Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course.

Authors:  Thorvardur Jon Love; Bjorn Gudbjornsson; Johann Eli Gudjonsson; Helgi Valdimarsson
Journal:  J Rheumatol       Date:  2007-08-01       Impact factor: 4.666

Review 10.  Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.

Authors:  Philip J Mease; April W Armstrong
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

View more
  9 in total

Review 1.  Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach.

Authors:  Elisa Visalli; Natascia Crispino; Rosario Foti
Journal:  Adv Ther       Date:  2019-02-25       Impact factor: 3.845

Review 2.  Strategies to Improve Outcomes in Psoriatic Arthritis.

Authors:  Christopher Ritchlin; Jose U Scher
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

3.  Development of a digital toolkit to improve quality of life of patients with systemic lupus erythematosus.

Authors:  Jerik Leung; Laura Kloos; Alfred Hj Kim; Elizabeth A Baker
Journal:  Digit Health       Date:  2021-08-10

4.  Clinicians' perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: an interview study.

Authors:  Daniel Sumpton; Elyssa Hannan; Ayano Kelly; David Tunnicliffe; Andrew Ming; Geraldine Hassett; Jonathan C Craig; Allison Tong
Journal:  Clin Rheumatol       Date:  2020-09-15       Impact factor: 2.980

5.  LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.

Authors:  Masato Okada; Sarina Kurimoto; Fabiana Ganz; Wolf-Henning Boehncke
Journal:  PLoS One       Date:  2021-01-27       Impact factor: 3.240

Review 6.  Multidisciplinary working in the management of axial and peripheral spondyloarthritis.

Authors:  Tania Gudu; Deepak R Jadon
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-10       Impact factor: 5.346

7.  Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.

Authors:  Dafna D Gladman; Laura C Coates; Joseph Wu; Lara Fallon; Elizabeth D Bacci; Joseph C Cappelleri; Andrew G Bushmakin; Philip S Helliwell
Journal:  Arthritis Res Ther       Date:  2022-02-09       Impact factor: 5.156

8.  A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project.

Authors:  Francesco Cusano; Francesca Sampogna; Alexandra Maria Giovanna Brunasso Vernetti; Stefano Stisi; Gilda Sandri; Giovanna Malara; Luigi Naldi; Michele Pellegrino; Giovanni Luigi Tripepi; Umberto di Luzio Paparatti; Concetto Paolo Agnusdei; Claudio Bonifati; Antonella Celano; Valeria Corazza; Federica D'Agostino; Rocco De Pasquale; Emilio Filippucci; Rosario Foti; Giovanna Galdo; Fabiana Gai; Giulia Ganzetti; Dario Graceffa; Mara Maccarone; Annamaria Mazzotta; Gennaro Melchionda; Francesca Molinaro; Franco Paoletti; Silvia Tonolo; Adriano Vercellone; Rosetta Vitetta; Cesare Massone; Gian Domenico Sebastiani
Journal:  Dermatol Reports       Date:  2022-09-26

9.  Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection.

Authors:  Pablo Coto; Sabino Riestra; Paloma Rozas; Ana Señaris; Rubén Queiro
Journal:  Ther Adv Chronic Dis       Date:  2020-02-12       Impact factor: 5.091

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.